CIBUS INC (CBUS) Fundamental Analysis & Valuation

NASDAQ:CBUS • US17166A1016

3.33 USD
+0.17 (+5.38%)
Last: Mar 9, 2026, 09:49 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CBUS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Overall CBUS gets a fundamental rating of 2 out of 10. We evaluated CBUS against 519 industry peers in the Biotechnology industry. CBUS has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, CBUS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. CBUS Profitability Analysis

1.1 Basic Checks

  • CBUS had negative earnings in the past year.
  • CBUS had a negative operating cash flow in the past year.
  • In the past 5 years CBUS always reported negative net income.
  • CBUS had a negative operating cash flow in each of the past 5 years.
CBUS Yearly Net Income VS EBIT VS OCF VS FCFCBUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

  • CBUS has a better Return On Assets (-36.01%) than 61.08% of its industry peers.
  • CBUS's Return On Equity of -235.91% is on the low side compared to the rest of the industry. CBUS is outperformed by 69.94% of its industry peers.
Industry RankSector Rank
ROA -36.01%
ROE -235.91%
ROIC N/A
ROA(3y)-65.46%
ROA(5y)-69.14%
ROE(3y)-199.52%
ROE(5y)-185.43%
ROIC(3y)N/A
ROIC(5y)N/A
CBUS Yearly ROA, ROE, ROICCBUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

  • CBUS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CBUS Yearly Profit, Operating, Gross MarginsCBUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. CBUS Health Analysis

2.1 Basic Checks

  • CBUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CBUS has been increased compared to 1 year ago.
  • The number of shares outstanding for CBUS has been increased compared to 5 years ago.
  • The debt/assets ratio for CBUS has been reduced compared to a year ago.
CBUS Yearly Shares OutstandingCBUS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
CBUS Yearly Total Debt VS Total AssetsCBUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • CBUS has an Altman-Z score of -3.73. This is a bad value and indicates that CBUS is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -3.73, CBUS perfoms like the industry average, outperforming 42.97% of the companies in the same industry.
  • A Debt/Equity ratio of 0.00 indicates that CBUS is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.00, CBUS is in line with its industry, outperforming 49.90% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.73
ROIC/WACCN/A
WACC8.78%
CBUS Yearly LT Debt VS Equity VS FCFCBUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

  • CBUS has a Current Ratio of 1.28. This is a normal value and indicates that CBUS is financially healthy and should not expect problems in meeting its short term obligations.
  • CBUS's Current ratio of 1.28 is on the low side compared to the rest of the industry. CBUS is outperformed by 83.24% of its industry peers.
  • CBUS has a Quick Ratio of 1.28. This is a normal value and indicates that CBUS is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.28, CBUS is doing worse than 82.66% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.28
Quick Ratio 1.28
CBUS Yearly Current Assets VS Current LiabilitesCBUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CBUS Growth Analysis

3.1 Past

  • CBUS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 82.01%, which is quite impressive.
  • The Revenue has decreased by -8.64% in the past year.
  • Measured over the past years, CBUS shows a very negative growth in Revenue. The Revenue has been decreasing by -10.20% on average per year.
EPS 1Y (TTM)82.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-833.33%
Revenue 1Y (TTM)-8.64%
Revenue growth 3Y-45.26%
Revenue growth 5Y-10.2%
Sales Q2Q%-63.11%

3.2 Future

  • Based on estimates for the next years, CBUS will show a very strong growth in Earnings Per Share. The EPS will grow by 20.85% on average per year.
  • Based on estimates for the next years, CBUS will show a very strong growth in Revenue. The Revenue will grow by 107.38% on average per year.
EPS Next Y9.85%
EPS Next 2Y22.54%
EPS Next 3Y16.1%
EPS Next 5Y20.85%
Revenue Next Year-2.2%
Revenue Next 2Y39.55%
Revenue Next 3Y59.92%
Revenue Next 5Y107.38%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CBUS Yearly Revenue VS EstimatesCBUS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M
CBUS Yearly EPS VS EstimatesCBUS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60

More info and screens

Find the best growth stocksShow best growing peers

0

4. CBUS Valuation Analysis

4.1 Price/Earnings Ratio

  • CBUS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CBUS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CBUS Price Earnings VS Forward Price EarningsCBUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CBUS Per share dataCBUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

  • CBUS's earnings are expected to grow with 16.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.54%
EPS Next 3Y16.1%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CBUS Dividend Analysis

5.1 Amount

  • CBUS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CBUS Fundamentals: All Metrics, Ratios and Statistics

CIBUS INC

NASDAQ:CBUS (3/9/2026, 9:49:42 AM)

3.33

+0.17 (+5.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-17
Inst Owners17.36%
Inst Owner Change4.15%
Ins Owners24.88%
Ins Owner Change5.91%
Market Cap226.11M
Revenue(TTM)3.79M
Net Income(TTM)-118.90M
Analysts80
Price Target14.59 (338.14%)
Short Float %3.77%
Short Ratio4.37
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.66%
Min EPS beat(2)13.74%
Max EPS beat(2)17.57%
EPS beat(4)2
Avg EPS beat(4)2.11%
Min EPS beat(4)-12.97%
Max EPS beat(4)17.57%
EPS beat(8)3
Avg EPS beat(8)-86.86%
EPS beat(12)4
Avg EPS beat(12)-138.03%
EPS beat(16)8
Avg EPS beat(16)-94.55%
Revenue beat(2)0
Avg Revenue beat(2)-38.42%
Min Revenue beat(2)-56.66%
Max Revenue beat(2)-20.19%
Revenue beat(4)1
Avg Revenue beat(4)-20.71%
Min Revenue beat(4)-56.66%
Max Revenue beat(4)5.12%
Revenue beat(8)5
Avg Revenue beat(8)48.49%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.69%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-11.05%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.98%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 59.6
P/FCF N/A
P/OCF N/A
P/B 4.49
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.66
EYN/A
EPS(NY)-1.53
Fwd EYN/A
FCF(TTM)-0.76
FCFYN/A
OCF(TTM)-0.75
OCFYN/A
SpS0.06
BVpS0.74
TBVpS-3.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -36.01%
ROE -235.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-65.46%
ROA(5y)-69.14%
ROE(3y)-199.52%
ROE(5y)-185.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.76%
Cap/Sales 14.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.28
Quick Ratio 1.28
Altman-Z -3.73
F-Score5
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)67.73%
Cap/Depr(5y)64.06%
Cap/Sales(3y)402.26%
Cap/Sales(5y)243.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)82.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-833.33%
EPS Next Y9.85%
EPS Next 2Y22.54%
EPS Next 3Y16.1%
EPS Next 5Y20.85%
Revenue 1Y (TTM)-8.64%
Revenue growth 3Y-45.26%
Revenue growth 5Y-10.2%
Sales Q2Q%-63.11%
Revenue Next Year-2.2%
Revenue Next 2Y39.55%
Revenue Next 3Y59.92%
Revenue Next 5Y107.38%
EBIT growth 1Y7.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year66.52%
EBIT Next 3Y29.41%
EBIT Next 5Y22.66%
FCF growth 1Y-40.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-55.43%
OCF growth 3YN/A
OCF growth 5YN/A

CIBUS INC / CBUS FAQ

Can you provide the ChartMill fundamental rating for CIBUS INC?

ChartMill assigns a fundamental rating of 2 / 10 to CBUS.


What is the valuation status of CIBUS INC (CBUS) stock?

ChartMill assigns a valuation rating of 0 / 10 to CIBUS INC (CBUS). This can be considered as Overvalued.


Can you provide the profitability details for CIBUS INC?

CIBUS INC (CBUS) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for CBUS stock?

The Earnings per Share (EPS) of CIBUS INC (CBUS) is expected to grow by 9.85% in the next year.